Q1 Earnings Estimate for CNTX Issued By William Blair

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at William Blair issued their Q1 2025 EPS estimates for Context Therapeutics in a note issued to investors on Monday, April 21st. William Blair analyst M. Phipps anticipates that the company will earn ($0.05) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.40) EPS and FY2028 earnings at ($0.55) EPS.

A number of other research analysts also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Wednesday, April 9th. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities initiated coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Context Therapeutics has a consensus rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Stock Performance

CNTX opened at $0.94 on Wednesday. The company’s 50-day simple moving average is $0.77 and its two-hundred day simple moving average is $1.22. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75. The stock has a market capitalization of $84.65 million, a P/E ratio of -1.04 and a beta of 2.18.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently made changes to their positions in the company. State Street Corp lifted its stake in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Franklin Resources Inc. purchased a new position in Context Therapeutics during the 3rd quarter worth $3,689,000. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after purchasing an additional 21,804 shares during the period. Geode Capital Management LLC grew its holdings in Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after acquiring an additional 52,830 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in Context Therapeutics in the fourth quarter worth approximately $94,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.